Trials / Available
AvailableNCT07244289
Managed Access Programs for VAY736, Ianalumab
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to VAY736, ianalumab
Detailed description
* CVAY736I12003M - Available - Managed Access Program (MAP) Cohort Treatment Plan CVAY736I12003M to provide access to ianalumab (VAY736) for patients with Primary Immune Thrombocytopenia (ITP) * CVAY736A1002M - Available - Managed Access Program (MAP) Cohort Treatment Plan CVAY736A1002M to provide access to ianalumab for adult patients with Sjögren's disease * CVAY736A1003I - Available - Managed Access Program (MAP) Individual Patient Request (IPR) Cover Letter CVAY736A1003I to provide access to Ianalumab (VAY736) for Sjögren's Disease * CVAY736I12004I - Available - Managed Access Program (MAP) Individual Patient Request (IPR) Cover Letter CVAY736I12004I to provide access to Ianalumab (VAY736) for Primary Immune Thrombocytopenia (ITP) and Evans syndrome
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ianalumab | Patients receive ianalumab |
Timeline
- First posted
- 2025-11-24
- Last updated
- 2026-03-23
Source: ClinicalTrials.gov record NCT07244289. Inclusion in this directory is not an endorsement.